Off Targets
THE POWER OF REPURPOSING

SPECIALTY PHARMACEUTICAL R&D
COMPANY OVERVIEW
United Kingdom · India

Known molecules. Differentiated by design.

Off Targets develops complex injectable, sterile, and advanced-delivery formulations from known molecules — engineering formulation complexity into real clinical and commercial differentiation, and real barriers to entry.

INVESTMENT THESIS

Complexity Premium

High barriers to entry — regulatory, capital, technical — keep these markets meaningfully less crowded than standard generics.

Capital Efficiency

Full NCE development is commonly cited at ~$2.6B over 10–15 years. Known-molecule development is typically a fraction of both.

Widening Opportunity

A significant wave of injectable and complex-drug patent expirations is expanding the pool of addressable molecules.

DEVELOPMENT MODEL

01 Concept & Selection

02 Formulation Development

03 Scale-Up & Clinical Readiness

04 Technology Transfer

05 Regulatory Batch Mfg.

06 Commercial Mfg. & Supply

FOCUS AREAS

Therapeutic Areas

Oncology · CNS Disorders · Critical Care · Pain Management · Anti-Infectives · Ophthalmology · Cardiovascular Acute Care · Parenteral Nutrition · Rare & Niche Hospital Indications

Dosage Forms & Delivery

Long-Acting Injectables · Pre-Filled Syringes · Ready-to-Use · Lyophilised · Emulsions & Suspensions · Nanoparticles · Ophthalmics · Oral Solids · Oral Liquids

PIPELINE SNAPSHOT

- **4** Long-Acting Injectable
- **5** Pre-Filled Syringe
- **3** Ready-to-Use
- **3** Lyophilised
- **3** Emulsions
- **10+** Oral Solids (developed to date)

Program-level detail (target product profiles, regulatory pathway, timelines) available to qualified partners under NDA.

BUSINESS MODEL

Disciplined Selection
Unmet need, market attractiveness, regulatory feasibility, competitive barriers, licensing potential.

R&D Infrastructure
Owned lab, Bangalore — 50+ scientists, plus academic-partner access to SEM, XRD, LC-MS, NGS, HTS.

Global Partner Network
Pharma companies, investors, CROs, CDMOs across UK, India, and global markets.

Licensing & Tech Transfer
Development-ready assets licensed, co-developed, or transferred for commercialisation.

GLOBAL OPERATIONS

United Kingdom — Business & Regulatory Gateway
Business development, licensing negotiations, IP strategy, and UK/EU regulatory positioning.

India, Bangalore — R&D Laboratory
Owned, state-of-the-art facility — 50+ scientists, plus academic access to NGS, Cryo-EM, NMR, HTS.

Interested in partnering, licensing, or investing?

business@offtargets.com

COMPLEX INJECTABLES
DIFFERENTIATED FORMULATIONS
UK & INDIA